Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada

BACKGROUND: Ovarian cancer is a leading cause of cancer-related mortality. Although the disease is relatively rare, it carries a disproportionately large morbidity burden. OBJECTIVE: We conducted a cost-utility analysis from a Canadian public payer perspective to determine the cost effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ball, Graeme, Xie, Feng, Tarride, Jean-Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820234/
https://www.ncbi.nlm.nih.gov/pubmed/29464667
http://dx.doi.org/10.1007/s41669-017-0030-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820234/
https://www.ncbi.nlm.nih.gov/pubmed/29464667
http://dx.doi.org/10.1007/s41669-017-0030-7

Ejemplares similares